Advertisement

Impact of HLA-G +3142C>G on the development of antibodies to blood group systems other than the Rh and Kell among sensitized patients with sickle cell disease

      Abstract

      Background

      Patients' inflammatory history is an important factor underlying red blood cell (RBC) alloimmunization, which is a frequent transfusion complication among individuals with sickle cell disease (SCD). HLA-G has been associated with different inflammatory and auto - immune diseases. Our goal was to verify whether the HLA-G + 3142 C>G and 14-bp Ins/Del variations are associated with RBC antibody development among SCD patients.

      Methods

      This was a single-center case-control study. SCD patients were randomly selected for the study and divided into two groups: ‘Alloimmunized’ and ‘Nonalloimmunized’ depending on the presence of irregular antibodies. The ‘Alloimmunized’group was further divided into two subgroups according to the presence of only antibodies against the Rh and Kell blood group systems or the existence of antibodies to antigens of the other blood group systems.

      Results

      A total of 213 patients were included in the study (110 alloimmunized and 103 non-alloimmunized). The ‘Alloimmunized’ and ‘Non-alloimmunized’ groups did not differ statistically regarding the HLA-G + 14 bp Ins/Del ( p = 0.494) and + 3142 C>G ( p = 0.334). Individuals who had only antibodies against the Rh and Kell antigens had a frequency of HLA-G + 3142GG genotype almost twice as high compared to the groupwith antibodies against less immunogenic antigens ( p = 0.043).

      Conclusions

      The genotype frequency of HLA-G + 3142 C>G differs among alloimmunized SCD patients, depending on the presence of antibodies against low immunogenic RBC antigens. This highlights a possible role played by the HLA-G molecule in the RBC alloimmunization process.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rosse W.F.
        • Gallagher D.
        • Kinney T.R.
        • Castro O.
        • Dosik H.
        • Moohr J.
        • Wang W.
        • Levy P.S.
        Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease.
        Blood. 1990; 76: 1431-1437
        • Miller S.T.
        • Kim H.Y.
        • Weiner D.L.
        • Wager C.G.
        • Gallagher D.
        • Styles L.A.
        • et al.
        Investigators of the sickle cell disease clinical research N. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010.
        Transfusion. 2013; 53: 704-709
        • Pirenne F.
        The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease.
        Curr Opin Hematol. 2019; 26: 488-494
        • Yazdanbakhsh K.
        Immunoregulatory networks in sickle cell alloimmunization.
        Hematology Am Soc Hematol Educ Program. 2016; 2016: 457-461
        • Higgins J.M.
        • Sloan S.R.
        Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders.
        Blood. 2008; 112: 2546-2553
        • Oliveira V.B.
        • Dezan M.R.
        • Gomes F.C.A.
        • Menosi Gualandro S.F.
        • Krieger J.E.
        • Pereira A.C.
        • Marsiglia J.D.
        • Levi J.E.
        • Rocha V.
        • Mendrone-Junior A.
        • Sabino E.C.
        • Dinardo C.L.
        -318C/T polymorphism of the CTLA-4 gene is an independent risk factor for RBC alloimmunization among sickle cell disease patients.
        Int J Immunogenet. 2017; 44: 219-224
        • Arnaiz-Villena A.
        • Juarez I.
        • Suarez-Trujillo F.
        • Lopez-Nares A.
        • Vaquero C.
        • Palacio-Gruber J.
        • et al.
        HLA-G: function, polymorphisms and pathology.
        Int J Immunogenet. 2021; 48: 172-192
        • Carosella E.D.
        • HoWangYin K.Y.
        • Favier B.
        • LeMaoult J.
        HLA-G-dependent suppressor cells: Diverse by nature, function, and significance.
        Hum Immunol. 2008; 69: 700-707
        • Veit T.D.
        • Cordero E.A.
        • Mucenic T.
        • Monticielo O.A.
        • Brenol J.C.
        • Xavier R.M.
        • Delgado-Canedo A.
        • Chies J.A.
        Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus.
        Lupus. 2009; 18: 424-430
        • Rizzo R.
        • Farina I.
        • Bortolotti D.
        • Galuppi E.
        • Rotola A.
        • Melchiorri L.
        • Ciancio G.
        • Di Luca D.
        • Govoni M.
        HLA-G may predict the disease course in patients with early rheumatoid arthritis.
        Hum Immunol. 2013; 74: 425-432
        • Tan Z.
        • Randall G.
        • Fan J.
        • Camoretti-Mercado B.
        • Brockman-Schneider R.
        • Pan L.
        • Solway J.
        • Gern J.E.
        • Lemanske R.F.
        • Nicolae D.
        • Ober C.
        Allele-specific targeting of microRNAs to HLA-G and risk of asthma.
        Am J Hum Genet. 2007; 81: 829-834
        • Hashemi M.
        • Sandoughi M.
        • Fazeli S.A.
        • Bahari G.
        • Rezaei M.
        • Zakeri Z.
        Evaluation of HLA-G 14 bp Ins/Del and +3142G>C polymorphism with susceptibility and early disease activity in rheumatoid arthritis.
        Adv Med. 2016; 20164985745
        • Thude H.
        • Janssen M.
        • Sterneck M.
        • Nashan B.
        • Koch M.
        14-bp ins/del polymorphism and +3142C>G SNP of the HLA-G gene have a significant impact on acute rejection after liver transplantation.
        Hum Immunol. 2016; 77: 1159-1165
        • Green M.R.
        • Sambrook J.
        Isolation of High-Molecular-Weight DNA Using Organic Solvents.
        Cold Spring Harb Protoc. 2017; 2017 (: pdb prot093450.)093450
        • Durmanova V.
        • Bandzuchova H.
        • Zilinska Z.
        • Tirpakova J.
        • Kuba D.
        • Buc M.
        • et al.
        Association of HLA-G Polymorphisms in the 3′UTR Region and Soluble HLA-G with Kidney Graft Outcome.
        Immunol Invest. 2019; 48: 644-658
        • Gonzalez A.
        • Rebmann V.
        • LeMaoult J.
        • Horn P.A.
        • Carosella E.D.
        • Alegre E.
        The immunosuppressive molecule HLA-G and its clinical implications.
        Crit Rev Clin Lab Sci. 2012; 49: 63-84
        • Baricordi O.R.
        • Stignani M.
        • Melchiorri L.
        • Rizzo R.
        HLA-G and inflammatory diseases.
        Inflamm Allergy Drug Targets. 2008; 7: 67-74
        • Hendrickson J.E.
        Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.
        Ann Blood. 2020; 5 (3-33): 3
        • Dezan M.
        • Oliveira V.
        • Bianchi J.
        • Rodrigues V.
        • Solano J.
        • Gomes F.
        • et al.
        Effectiveness of a red cell antigen‐matching transfusion protocol in sickle cell disease patients.
        ISBT Sci Series. 2016; 11: 132-139
        • Alves C.C.
        • Arruda L.K.P.
        • Oliveira F.R.
        • Massaro J.D.
        • Aquino B.J.
        • Paz M.A.
        • et al.
        Human leukocyte antigen-G 3′ untranslated region polymorphisms are associated with asthma severity.
        Mol Immunol. 2018; 101: 500-506
        • Medeiros F.S.
        • Martins A.E.S.
        • Gomes R.G.
        • de Oliveira S.A.V.
        • Welkovic S.
        • Maruza M.
        • et al.
        Variation sites at the HLA-G 3′ untranslated region confer differential susceptibility to HIV/HPV co-infection and aneuploidy in cervical cell.
        PLoS One. 2018; 130204679
        • Meinderts S.M.
        • Sins J.W.R.
        • Fijnvandraat K.
        • Nagelkerke S.Q.
        • Geissler J.
        • Tanck M.W.
        • Bruggeman C.
        • Biemond B.J.
        • Rijneveld A.W.
        • Kerkhoffs J.H.
        • Pakdaman S.
        • Habibi A.
        • van Bruggen R.
        • Kuijpers T.W.
        • Pirenne F.
        • van den Berg T.K.
        Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease.
        Blood. 2017; 130: 2121-2130